Table 2.
Quality assessment with the PEDro scale.
| Article | Items by number on the PEDro scale | Total score | Subjects | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | |||
| Lam et al. (50) | y | y | y | y | n | n | y | n | n | y | y | 6 | Older adults |
| Wei et al. (69) | y | y | n | y | n | n | n | y | y | y | y | 6 | |
| Goudarzian et al. (45) | y | y | n | y | n | n | n | y | n | y | y | 5 | |
| Sitjà-Rabert et al. (64) | y | y | y | n | n | n | y | n | y | y | y | 6 | |
| Santin-Medeiros et al. (62) | y | y | n | n | n | n | n | n | y | y | y | 4 | |
| Buckinx et al. (36) | y | y | n | n | n | n | y | n | y | y | y | 5 | |
| Lee et al. (53) | y | y | n | y | n | n | n | y | n | y | y | 5 | |
| Beaudart et al. (31) | y | y | n | y | n | n | y | y | y | y | y | 7 | |
| Gómez-Cabello et al. (44) | n | y | n | n | n | n | n | y | y | y | y | 5 | |
| Bogaerts, et al. (32) | y | y | y | y | n | n | n | y | n | y | y | 6 | |
| Machado et al. (55) | y | y | n | n | n | n | y | y | n | y | y | 5 | |
| Mikhael et al. (56) | y | y | y | y | y | n | y | n | n | y | y | 7 | |
| Furness and Maschette (40) | y | y | n | n | n | n | n | y | y | y | y | 5 | |
| Rees et al. (59) | y | y | n | y | n | n | n | y | n | y | y | 5 | |
| Bautmans et al. (30) | y | y | y | y | y | n | y | y | n | y | y | 8 | |
| Bruyere et al. (9) | y | y | n | n | n | n | n | y | y | y | y | 5 | |
| Spielmanns et al. (71) | y | y | y | y | n | n | n | n | n | y | y | 5 | COPD |
| Spielmanns et al. (65) | y | y | n | y | n | n | n | y | n | y | y | 5 | |
| Salhi et al. (61) | y | y | y | y | n | n | n | n | n | y | y | 6 | |
| Pleguezuelos et al. (57) | y | y | n | y | n | n | y | n | n | y | y | 5 | |
| Alp et al. (28) | y | y | y | n | n | n | y | y | n | y | y | 6 | Stroke |
| Choi et al. (72) | y | y | y | y | n | n | y | y | y | y | y | 8 | |
| Choi et al. (38) | y | y | n | y | n | n | n | n | n | y | y | 4 | |
| Liao et al. (54) | y | y | y | y | n | n | y | y | y | y | y | 8 | |
| Lau et al. (51) | y | y | y | y | n | n | y | y | y | y | y | 8 | |
| Brogårdh et al. (35) | y | y | y | y | y | n | y | y | y | y | y | 9 | |
| van Nes Ilse et al. (67) | y | y | y | n | y | n | y | y | y | y | y | 8 | |
| Bokaeian et al. (33) | y | y | y | y | n | n | n | y | n | y | y | 6 | Knee OA |
| Wang et al. (68) | y | y | y | y | n | n | y | y | y | y | y | 8 | |
| Simão et al. (63) | y | y | y | y | n | n | y | y | n | y | y | 7 | |
| Avelar et al. (29) | y | y | n | y | n | n | n | y | n | y | y | 5 | |
| Sucuoglu al. (66) | y | y | n | y | n | n | n | n | n | y | y | 4 | Postmenauposal women |
| Iwamoto et al. (48) | y | y | n | y | n | n | n | y | y | y | y | 6 | |
| Raimundo et al. (58) | y | y | n | y | n | n | n | n | n | y | y | 4 | |
| Ebrahimi et al. (39) | y | y | n | y | n | n | n | y | n | y | y | 5 | Multiple sclerosis |
| Broekmans et al. (34) | y | y | y | y | n | n | y | y | n | y | y | 7 | |
| In et al. (47) | y | y | y | y | y | n | y | y | n | y | y | 8 | Other pathologies in adults |
| Gerhardt et al. (42) | y | y | n | y | n | n | n | n | n | y | y | 4 | |
| Gloeckl et al. (43) | y | y | y | y | n | n | y | n | n | y | y | 6 | |
| Gaßner et al. (41) | y | y | n | y | n | n | n | y | n | y | y | 5 | |
| Johnson et al. (49) | y | y | n | n | n | n | n | n | n | y | y | 3 | |
| Ahlborg et al. (27) | y | y | n | y | n | n | n | y | y | y | y | 6 | |
| Högler et al. (46) | y | y | y | y | n | n | n | n | n | y | y | 5 | Other pathologies in children |
| Cheng et al. (37) | y | y | n | y | n | n | n | y | y | y | y | 6 | |
| Lee et al. (53) | y | y | y | y | n | n | y | y | y | y | y | 8 | |
| Ruck et al. (60) | y | y | y | y | n | n | n | n | n | y | y | 5 | |
n, criterion not fulfilled; y, criterion fulfilled; 1, eligibility criteria were specified; 2, subjects were randomly allocated to groups or to a treatment order; 3, allocation was concealed; 4, the groups were similar at baseline; 5, there was blinding of all subjects; 6, there was blinding of all therapists; 7, there was blinding of all assessors; 8, measures of at least one key outcome were obtained from more than 85% of the subjects who were initially allocated to groups; 9, intention-to-treat analysis was performed on all subjects who received the treatment or control condition as allocated; 10, the results of between-group statistical comparisons are reported for at least one key outcome; 11, the study provides both point measures and measures of variability for at least one key outcome; total score, each satisfied item (except the first) contributes 1 point to the total score, yielding a PEDro scale score that can range from 0 to 10. B, the level of evidence was B (randomized control trials that lacked double-blinding).